7,580.07

-140.32

-1.82%

51,770.31

-572.29

-1.09%

25,437.00

-747.70

-2.86%

2,811.84

-47.38

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,835.43

+311.50

+0.40%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

HKSE - Delayed Quote HKD

Lepu Biopharma Co., Ltd. (2157.HK)

3.155 +0.090 (+2.94%)

At close: October 30 at 4:08:06 PM GMT+8

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Lepu Biopharma (SEHK:2157) Rebounds In The Short Term While Valuation Stays In Focus

Simply Wall St. 3mo ago

2157.HK
+2.94%
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

GlobeNewswire 7d ago

AVBP

2157.HK
+2.94%
AstraZeneca Cancer Drug Targets Up to $5 Billion in Sales

GuruFocus.com 3mo ago

2162.HK

AZN

2157.HK
+2.94%
BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC

PR Newswire 11mo ago

2157.HK
+2.94%
1875.HK
BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC

PR Newswire 11mo ago

2157.HK
+2.94%
1875.HK

Performance Overview

Return	2157.HK	HANG SENG INDEX (^HSI)
YTD	-36.90%	-9.11%
1-Year	-50.70%	-11.37%
3-Year	-19.10%	+33.83%

Mobilize your Website

View Site in Mobile | Classic

Share by: